Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRx0518
- Development stage
- Phase 1
- Lead developer
- 4D pharma
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
MRx0518 is an oral live biotherapeutic product derived from the gut microbiome and developed by 4D pharma for cancer immunotherapy. Public descriptions identify it as a microbiome-based, immunostimulatory bacterial therapy, with published work linking its activity to **Enterococcus gallinarum MRx0518** and especially its flagellin-mediated innate immune activation. Clinically, MRx0518 has been studied as monotherapy in a neoadjuvant pre-surgical setting in treatment-naive patients with solid tumors and in combination with immune checkpoint inhibitors such as pembrolizumab and avelumab to enhance anti-tumor immune responses and potentially overcome resistance to prior PD-1 blockade. Development has focused on solid tumors including urothelial carcinoma, pancreatic cancer, melanoma, renal cell carcinoma, bladder cancer, non-small cell lung cancer, and other surgically resectable malignancies.
02
Targets
TLR5
Beyond the preview
Go deeper on MRx0518.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRx0518.